InnoCan Pharma (DB:IP4) - Hisse Senedi Fiyatı, Haberler ve Analizler

IP4 Stoklara Genel Bakış

IP4 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 10.5% oranında arttı

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Anlamlı bir piyasa değeri yok ( €60M )

Hissedarlar geçen yıl sulandırıldı

InnoCan Pharma Corporation Rakipler

MPH Health Care

DB:93M1

€103.6m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€55.6m

Pierrel

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti InnoCan Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.16
52 Haftanın En Yüksek Seviyesi	CA$0.28
52 Haftanın En Düşük Seviyesi	CA$0.13
Beta	2.96
11 Aylık Değişim	6.33%
3 Aylık Değişim	-4.78%
1 Yıllık Değişim	-26.33%
33 Yıllık Değişim	-76.12%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	431.67%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IP4	DE Pharmaceuticals	DE Pazar
7D	8.5%	-5.0%	-1.3%
1Y	-26.3%	-22.0%	7.4%

Getiri vs. Endüstri: IP4 geçen yıl % -22 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: IP4 geçen yıl % 7.4 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IP4's price volatile compared to industry and market?
IP4 volatility
IP4 Average Weekly Movement	11.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: IP4 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IP4 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2018	n/a	Iris Bincovich	innocanpharma.com

Bir farmasötik teknoloji şirketi olan InnoCan Pharma Corporation, Amerika Birleşik Devletleri, Kanada, Avrupa ve uluslararası alanda kannabidiolü (CBD) diğer farmasötik bileşenlerle birleştiren çeşitli ilaç dağıtım platformlarının geliştirilmesine odaklanmaktadır. Şirket, Farmasötikler ve Tüketici Sağlığı olmak üzere iki segmentte faaliyet göstermektedir. CBD yüklü ekzozomların araştırılması ve geliştirilmesinin yanı sıra, epilepsi ve ağrı yönetimi için CBD'nin kan dolaşımına tam olarak dozlanmasını ve uzun süreli ve kontrollü salınımını kolaylaştıran LPT CBD yüklü lipozom platformunu işletmektedir.

InnoCan Pharma Corporation Temel Bilgiler Özeti

InnoCan Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IP4 temel i̇stati̇sti̇kler
Piyasa değeri	€41.15m
Kazançlar(TTM)	-€2.48m
Gelir(TTM)	€27.60m

1.6x

P/S Oranı

-17.4x

F/K Oranı

IP4 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IP4 gelir tablosu (TTM)
Gelir	US$28.93m
Gelir Maliyeti	US$2.86m
Brüt Kâr	US$26.07m
Diğer Giderler	US$28.67m
Kazançlar	-US$2.60m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.0091
Brüt Marj	90.11%
Net Kâr Marjı	-9.00%
Borç/Özkaynak Oranı	0%

IP4 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IP4 Stoklara Genel Bakış

Ödüller

Risk Analizi

InnoCan Pharma Corporation Rakipler

DB:93M1

€103.6m

DB:0RX

€65.0m

XTRA:HIGH

€55.6m

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding

Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023)

Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center

First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)

Recent updates

Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding

Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023)

Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center

First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)

Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding

Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology

First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022)

InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial

Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021)

InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding

Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021)

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy

Second quarter 2022 earnings released

InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain

InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms

InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT

Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management

Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

Less than half of directors are independent

InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform

Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study

Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform

New 90-day high: €0.33

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions

New 90-day high: €0.26

InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes

InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding

New 90-day high: €0.26

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA

Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

New 90-day high: €0.23

Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD